Jove
Visualize
Contact Us

Related Concept Videos

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

259
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
259
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

273
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
273
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

168
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
168
Birth Control Methods01:22

Birth Control Methods

5.5K
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
5.5K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

282
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
282

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the association between polycystic ovary syndrome and female sexual dysfunction: a cross-sectional study.

Reproductive biology and endocrinology : RB&E·2025
Same author

Association of Migraine and Vasomotor Symptoms.

Mayo Clinic proceedings·2023
Same author

Evaluating the Link Between Self-Reported Endometriosis and Female Sexual Dysfunction.

The journal of sexual medicine·2022
Same author

Sexual dysfunction in female cancer survivors: Addressing the problems and the remedies.

Maturitas·2022
Same author

Contemporary Non-hormonal Therapies for the Management of Vasomotor Symptoms Associated with Menopause: A Literature Review.

TouchREVIEWS in endocrinology·2022
Same author

Assessing age, breeding stage, and mating activity as drivers of variation in the reproductive microbiome of female tree swallows.

Ecology and evolution·2021
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Apr 28, 2026

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration
06:51

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration

Published on: June 7, 2012

58.0K

Compounded estradiol cream: a cost conscious alternative.

Benjamin J Barenberg, Taryn Smith, Mikio A Nihira

    The Journal of the Oklahoma State Medical Association
    |June 7, 2014
    PubMed
    Summary

    Compounded vaginal estrogen offers significant cost savings for patients. Utilizing compounding pharmacies can reduce expenses by over 50% compared to branded preparations, improving medication accessibility.

    Area of Science:

    • Gynecology
    • Pharmacology
    • Health Economics

    Background:

    • Topical vaginal estrogen is a widely used treatment for various gynecologic conditions.
    • High medication costs can impede patient adherence to prescribed therapies.
    • Investigating cost-effective alternatives is crucial for improving treatment compliance.

    Purpose of the Study:

    • To quantify patient cost savings associated with using compounded vaginal estrogen.
    • To compare the expenses of compounded estrogen preparations versus commercially available branded options.

    Main Methods:

    • A survey was conducted involving 10 compounding pharmacies specializing in topical vaginal estrogen.
    • Prescription cost data for compounded and branded estrogen preparations were collected.

    More Related Videos

    An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
    06:18

    An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

    Published on: August 13, 2019

    11.7K
    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
    11:39

    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

    Published on: July 11, 2013

    38.4K

    Related Experiment Videos

    Last Updated: Apr 28, 2026

    Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration
    06:51

    Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration

    Published on: June 7, 2012

    58.0K
    An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
    06:18

    An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

    Published on: August 13, 2019

    11.7K
    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
    11:39

    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

    Published on: July 11, 2013

    38.4K
  • Cost comparisons were made against a university outpatient pharmacy and a national pharmaceutical database.
  • Descriptive statistics were employed to analyze the collected cost data.
  • Main Results:

    • The average cost for compounded vaginal estrogen was $42.22.
    • Branded vaginal estrogen preparations averaged $137.70 locally and $82.42 nationally.
    • Significant cost savings were observed: 69% ($94.98) locally and 51% ($40.20) nationally.

    Conclusions:

    • Compounded vaginal estrogen presents a more affordable alternative to branded preparations.
    • The study highlights the potential for substantial patient savings through compounded formulations.
    • Cost-effective compounded estrogen can enhance medication compliance for gynecologic conditions.